A Response Letter to Kosaka et al. Regarding Manuscript Titled: "Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study".
作者信息
Brown Lauren Julia, Ahn Julie, Gao Bo, Gee Harriet, Nagrial Adnan, Silva Inês Pires da, Hau Eric
机构信息
Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia.
Blacktown Cancer and Haematology Centre, Blacktown Hospital, Sydney, New South Wales, Australia.
出版信息
JTO Clin Res Rep. 2024 Nov 17;6(2):100767. doi: 10.1016/j.jtocrr.2024.100767. eCollection 2025 Feb.
Abstract
摘要
相似文献
1
A Response Letter to Kosaka et al. Regarding Manuscript Titled: "Radiotherapy Improves Survival in Non-Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study".致小坂等人的回复信，关于题为《放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究》的手稿
JTO Clin Res Rep. 2024 Nov 17;6(2):100767. doi: 10.1016/j.jtocrr.2024.100767. eCollection 2025 Feb.
2
[Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].[免疫治疗期间寡进展的转移性非小细胞肺癌患者接受局部放疗的意义]
Bull Cancer. 2023 Dec;110(12):1234-1243. doi: 10.1016/j.bulcan.2023.09.006. Epub 2023 Oct 26.
3
Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.晚期非小细胞肺癌中免疫治疗应答者耐药后的进展模式、治疗及预后
Front Oncol. 2021 Mar 5;11:642883. doi: 10.3389/fonc.2021.642883. eCollection 2021.
4
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究。
JTO Clin Res Rep. 2024 May 30;5(10):100695. doi: 10.1016/j.jtocrr.2024.100695. eCollection 2024 Oct.
5
The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.立体定向体部放疗联合序贯免疫检查点抑制剂治疗寡进展期晚期非小细胞肺癌的疗效和安全性分析
Transl Cancer Res. 2024 May 31;13(5):2408-2418. doi: 10.21037/tcr-23-2232. Epub 2024 May 7.
6
Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy.一线免疫治疗下寡进展转移性 NSCLC 局部消融治疗患者的结局分析。
Clin Lung Cancer. 2024 Dec;25(8):e402-e410.e3. doi: 10.1016/j.cllc.2024.07.009. Epub 2024 Aug 8.
7
The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.放疗在表皮生长因子受体突变阳性寡进展患者中的作用：一项匹配队列分析
Clin Oncol (R Coll Radiol). 2017 Sep;29(9):568-575. doi: 10.1016/j.clon.2017.04.035. Epub 2017 May 9.
8
Letter Regarding "Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study".关于“放射治疗改善免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究”的信函
JTO Clin Res Rep. 2024 Nov 1;6(1):100760. doi: 10.1016/j.jtocrr.2024.100760. eCollection 2025 Jan.
9
Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.晚期非小细胞肺癌寡进展后立体定向体部放疗联合检查点抑制剂治疗
Transl Lung Cancer Res. 2021 Dec;10(12):4368-4379. doi: 10.21037/tlcr-21-682.
10
Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: A real-world study.EGFR 突变型非小细胞肺癌寡进展期持续使用 EGFR-TKIs 放疗的真实世界研究。
Cancer Med. 2023 Jan;12(1):266-273. doi: 10.1002/cam4.4894. Epub 2022 Jun 5.
本文引用的文献
1
Letter Regarding "Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study".关于“放射治疗改善免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究”的信函
JTO Clin Res Rep. 2024 Nov 1;6(1):100760. doi: 10.1016/j.jtocrr.2024.100760. eCollection 2025 Jan.
2
Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study.放射治疗可提高免疫治疗后寡进展的非小细胞肺癌患者的生存率：一项队列研究。
JTO Clin Res Rep. 2024 May 30;5(10):100695. doi: 10.1016/j.jtocrr.2024.100695. eCollection 2024 Oct.
3
Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌临床实践指南（第 4.2024 版），NCCN 肿瘤学临床实践指南
J Natl Compr Canc Netw. 2024 May;22(4):249-274. doi: 10.6004/jnccn.2204.0023.
4
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.标准治疗系统疗法联合或不联合立体定向体部放疗治疗寡进展性乳腺癌或非小细胞肺癌患者（放疗阻断寡进展[CURB]研究）：一项开放标签、随机、对照、2 期研究。
Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14.
5
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.从放射肿瘤学角度定义寡转移疾病：ESTRO-ASTRO 共识文件。
Radiother Oncol. 2020 Jul;148:157-166. doi: 10.1016/j.radonc.2020.04.003. Epub 2020 Apr 22.
6
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.立体定向体部放疗后帕博利珠单抗与单纯帕博利珠单抗治疗晚期非小细胞肺癌患者肿瘤反应的效果：PEMBRO-RT 2期随机临床试验结果
JAMA Oncol. 2019 Sep 1;5(9):1276-1282. doi: 10.1001/jamaoncol.2019.1478.
7
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.放疗和双重检查点阻断激活癌症中的非冗余免疫机制。
Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.
Zotero 插件